Aplastic Anemia News and Research

RSS

UMass Amherst study targets aplastic anemia with cell retraining approach

Researchers at the University of Massachusetts Amherst recently released a first-of-its-kind study that focuses on the rare autoimmune disorder aplastic anemia to understand how a subset of cells might be trained to correct the overzealous immune response that can lead to fatal autoimmune disorders.

27 Feb 2024

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

Study reveals how inflammation alters the tumor microenvironment in acute myeloid leukemia

Severe inflammation weakens the body's ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows.

11 Jan 2023

Rogue killer T cells associated with leukemia drive autoimmune diseases

Gene variants associated with leukemia can produce 'rogue' immune cells that drive autoimmune diseases, according to a new study from the Garvan Institute of Medical Research.

28 Nov 2022

First transfusions of lab-grown blood

Two patients in the United Kingdom received two small doses of lab-grown blood samples as part of the RESTORE trial.

9 Nov 2022

ASU scientists discover an unusual RNA biogenesis pathway

For the very first time, a study led by Julian Chen and his group in Arizona State University's School of Molecular Sciences and the Biodesign Institute's Center for the Mechanism of Evolution, has discovered an unprecedented pathway producing telomerase RNA from a protein-coding messenger RNA (mRNA).

3 Oct 2022

AAMDSIF Patient and Family Conference to be held in Memphis

The University of Tennessee Health Science Center is partnering with the Aplastic Anemia & MDS International Foundation (AAMDSIF), along with St. Jude Children's Research Hospital, Regional One Health, and Baptist Memorial Hospital, to hold the AAMDSIF Patient and Family Conference for the first time in Memphis on July 23.

22 Jul 2022

UC San Diego scientists develop new method to keep cultured cells healthy

Hematopoietic stem cells — the precursors to blood cells — have been notoriously difficult to grow in a dish, a critical tool in basic research.

12 Aug 2021

Researchers develop telomerase gene therapy for treating different pathologies

After several years of research and many joint scientific publications, molecular biologists Maria Blasco (National Cancer Research Centre, CNIO) and Fàtima Bosch (Universitat Autònoma de Barcelona, UAB) have developed a telomerase gene therapy for the treatment of different pathologies related to shortening telomeres and, therefore, ageing.

2 Dec 2020

Somatic mutation may act as a natural gene therapy in patients with rare autosomal disease

Researchers affiliated with the Center for Cell-Based Therapy in Ribeirão Preto, Brazil, have identified for the first time a non-hereditary mutation in blood cells from a patient with GATA2 deficiency, a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2).

17 Nov 2020

Two studies show the benefit of collaborative research on childhood blood disorders

When a child has a rare blood disorder, clinicians can struggle to find the best diagnostic and treatment methods.

15 Oct 2020

UM171 molecule saves life of young man suffering from severe aplastic anemia

In a world first, a young man suffering from severe aplastic anemia who could not be helped by standard treatments has been given a life-saving blood transplant with the made-in-Canada UM171 molecule.

30 Sep 2020

Triple therapy increases response rates in patients with Severe Aplastic Anemia

The European Society for Blood and Marrow Transplantation (EBMT), Europe's collaborative peer network of professionals working in the field of stem cell transplantation and cellular therapy, announced today the results of the phase III RACE trial during EBMTs virtual 46th Annual Meeting. Preliminary data show that adding Eltrombopag to standard immunosuppressive treatment is safe and increases response rates in patients with Severe Aplastic Anaemia.

31 Aug 2020

New study may offer a breakthrough in treating telomere diseases

Capping decades of research, a new study may offer a breakthrough in treating dyskeratosis congenita and other so-called telomere diseases, in which cells age prematurely.

21 Apr 2020

Rapamycin worsens diseases and premature aging in mice with short telomeres

In the past few decades, it was discovered that the rate at which we age is strongly influenced by biochemical processes that, at least in animal models, can be controlled in the laboratory.

3 Mar 2020

Lymphopenia may hint a higher risk of future illness, death

Lymphopenia, which indicates lower levels of lymphocytes in the blood, has been tied to a higher risk of future illness and death, a new study found.

13 Jan 2020

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Study suggests new approach to treat life-threatening blood disorder in children

Pediatric researchers studying the life-threatening blood disorder Fanconi anemia have devised a method to block the abnormal biological signals that drive the disease.

12 Oct 2018

Gene therapy with telomerase does not increase cancer risk, study shows

Negative results and findings in science are perhaps less newsworthy, but they are no less important. Particularly when, as in this case, they demonstrate that a possible new therapeutic pathway against idiopathic pulmonary fibrosis and other diseases associated to short telomeres is in fact safe.

21 Aug 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018